- Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3
- Fewer known CAR-T cell therapy adverse events for patients with DLBCL, specifically rates of high-grade cytokine release syndrome (4%) and neurologic events (5%), were observed compared with the pivotal clinical trials1-3
- In children and young adults with ALL, efficacy outcomes were similar and safety outcomes appear to be more favorable compared to the pivotal trial4
- Understanding the Kymriah safety profile, and increased experience with administration in real-world practice supports use in the outpatient setting
PR Newswire
EAST HANOVER, N.J., Dec. 9, 2019
